BRIEF RESEARCH REPORT article
Sec. Public Mental Health
Volume 13 - 2022 | https://doi.org/10.3389/fpsyt.2022.797150
Clinical Guidelines of the Egyptian Psychiatric Association for the Management of Treatment-Resistant Unipolar Depression in Egypt
- 1Department of Psychiatry, Kasr El-Aini Medical School, Cairo University, Giza, Egypt
- 2Okasha Institute of Psychiatry, Medical School, Ain Shams University, Cairo, Egypt
- 3Department of Psychiatry, Kasr El-Aini Medical School, Cairo University, Cairo, Egypt
- 4Department of Psychiatry, Alexandria Medical School, Alexandria University, Alexandria, Egypt
- 5Department of Psychiatry, Ain Shams Medical School, Ain Shams University, Cairo, Egypt
- 6Department of Psychiatry, Banha Medical School, Banha University, Benha, Egypt
- 7Department of Psychiatry, Beni-Suef Medical School, Beni-Suef University, Beni-Suef, Egypt
- 8Faculty of Pharmacy, German University of Cairo, Cairo, Egypt
Background: Major depressive disorder (MDD) is a public health burden that creates a strain not only on individuals, but also on the economy. Treatment-resistant depression in the course of major depressive disorder represents a clinically challenging condition that is defined as insufficient response to two or more antidepressant trails with antidepressants of the same or different classes that were administered at adequate daily doses for at least 4 weeks.
Objective/Hypothesis: To develop a treatment guideline for Treatment Resistant Depression (TRD).
Methodology: Experts in the field gathered and reviewed the available evidence about the subject. Then, a series of meetings were held to create recommendations that can be utilized by Egyptian psychiatrists.
Results: The guidelines provide recommendations in various clinical settings. It evaluates different situations, such as patients at risk of resistance, those with resistance and recommends strategies to resolve the clinical case.
Conclusion: The consensus guidelines will improve the outcomes of patients, as they provide recommendations across various domains that are of concern for the practicing psychiatrist.
MDD is defined as a disorder of having one or more major depressive episodes in a person's life with the absence of manic or hypomanic symptoms; to meet the criteria of MDD five out of nine symptoms, two of which must be low mood and anhedonia (loss of pleasure) persisting for a 2-week period. The nine symptoms include low mood, loss of interest or pleasure, disturbed sleep, change of eating pattern or weight, agitation or psychomotor slowness, unexplained fatigue, feeling worthless or guilty, inability to concentrate and thoughts of death or suicide (1).
Major depressive disorder (MDD) is a major public health concern. It is projected to be the first cause of disease burden worldwide by 2030 (2). According to the World Health Organization (WHO), depression affects over 260 million individuals worldwide (3). Results of a recent systematic review by Odejimi et al. reported that the prevalence of depression in Egypt ranges between 23.7 and 74.5% (4).
This mental disorder results from the interaction of several factors, including psychological, social and biological factors (5).
According to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), a person is diagnosed with MDD when he or she consistently depressed mood or anhedonia, along with five of the following symptoms; difficulty in concentration, appetite changes, decreased energy, sleep disturbance, suicidal thoughts and tendencies, concentration difficulties, or psychomotor agitation or depression (6).
In medicine, the term “resistance” is used to describe the failure of standard treatment; although there is no distinct definition for TRD as clinical practice is ever evolving and because treatment “failure” is sometimes judged by physicians themselves when their patients do not respond as much as they expected them to. In short, TRD is described as depression that is unresponsive to antidepressant drug treatment at adequate dosing for an adequate amount of time (5).
Response to traditional treatment has been assessed by several studies (6). One major trial highlighted that the remission rate after step 1 of treatment was 36.8%, with the remission rate decreasing after each step of treatment, reaching only 13% at the fourth step (7, 8). In other words, the more advancement in treatment lines, the more likely is the patient to relapse. The same study concluded that the overall remission rate was 67%, highlighting that about 1 in every 3 patients fails treatment (9).
Several psycho-pharmacotherapeutic strategies have been suggested to overcome TRD, whereby augmentation treatment represents the currently recommended first-choice in case of insufficient response to the initial antidepressant treatment. In accordance with available international evidence, second-generation antipsychotics or lithium should be preferably employed (6).
Many patients are labeled as treatment resistant mistakenly when they are actually pseudo-resistant cases of depression; most common causes of this case are due to sub-therapeutic dosing or non-adherence to medication. According to APA guidelines it is important for physicians to assess any patient comorbidities, modifying doses of first line treatment if it failed after 4 weeks, considering patient history when adding second line treatment to ensure that the patient will positively respond to the medication and only initiating second line treatment after unsatisfactory response at 4 weeks (9).
“According to available international evidence, this publication will cover treatment options and recommendations from the Egyptian Psychiatric Association for the management of TRD in the course of MDD in Egypt.”
Expert recommendations were determined after a thorough examination of available literature to identify and assess the recent global updates about the subject. Prior to the meeting, two senior members of the committee performed a comprehensive search on the PubMed database to identify the available literature relevant to the topic using keyword, such as “treatment-resistant depression”, “major depressive disorders” and their derivates. Then, those senior members prepared a questionnaire using the Delphi technique and invited committee members to assess the literature and respond to the questionnaire.
Afterwards, responses of clinicians to the questionnaire were captured, analyzed and ranked. Then, another round of questions was dispensed in a second meeting based on the outcomes of the first committee gathering and questionnaire responses. The second round was when a consensus was reached by all committee members, therefore there was no need for further meetings (10).
An expert panel of 8 professors of psychiatry from different universities and the ministry of health representing the Egyptian Psychiatric Association drafted the following guidelines. Information about panel members can be found in the Appendix.
Definition of Resistant Depression
According to a meta-analysis by Gaynes et al. 2019, there is no clear-cut definition for TRD, however, most experts unanimously agree that lack of response to initial treatment is deemed as TRD. The APA (American Psychological Association) and NICE (National Institute for Health and Care Excellence) guidelines also state that the next step of handling TRD also differs between experts which makes it more challenging to develop universal treatment guidelines. The classes of medications should be among the following: (11).
- Tricyclic antidepressants (TCAs) (equivalent to 300 mg imipramine) (12)
- Selective serotonin reuptake inhibitors (SSRIs) (equivalent to 50 mg fluoxetine) (13)
- Serotonin norepinephrine reuptake inhibitors (SNRIs) (equivalent to 225 mg venlafaxine) (14)
Antidepressant treatment has been the mainstay treatment of depression for years; the first class of such drugs were tricyclic antidepressants followed by more novel agents namely SSRIs and SNRIs. Both classes of TCA and SSRIs are equally affective in ameliorating depressive symptoms and decreasing depression scores as proved by a meta-analysis to compare the two classes. However, SSRIs are preferred by patients as well as physicians as they do not produce bothersome side effects as TCAs (15).
SNRIs are a group of antidepressants with a dual mechanism of action of both serotonin and adrenergic reuptake inhibition; research has suggested that SNRIs are superior to SSRIs in more severe depression; which insinuates their possible effectiveness in TRD. Moreover, SNRIs have established efficacy in treating depression with somatic manifestations as pain and other physical symptoms (16). The Danish guidelines; which incorporates the APA and NICE guidelines states that most patients first diagnosed with MDD are treated with SSRIs then switched to SNRIs. The ten most prescribed treatments for TRD mainly constitute of both SSRI's and SNRI's as first, second- and third-line treatments (17). Other antidepressants as trazodone, vilazodone and tranylcypromine are also available options however, are not easily accessible in the Egyptian market.
The advisory committee recommended of TRD be as follows:
Treatment-resistant depression shall be defined as the failure of 2 different classes of antidepressant medications, given that the medications have been used for a period of 6–8 weeks at the desired dose.
N.B. (Nota bene) to the above definition and in order to account for the definition of TRD in Egypt, the committee added 6–12 monitored sessions of BST (Brain Synchronization Therapy)/ECT (Electroconvulsive Therapy).
The panel recognized the importance of identifying the term “pseudo-resistance”, which was defined by the panel as a patient not responding to medication because of a problem in the diagnosis or the type of depression or the presence of depression secondary to another psychiatric, personality or medical disorder.
In addition to pseudo-resistance, the clinical experts highlighted additional predictors for TRD, as follows:
- Other forms of depression such as bipolar depression.
- Other comorbid conditions, including concurrent anxiety, drug abuse, chronic organic medical conditions, and personality-related disorders (e.g., mood swings in borderline personality disorder).
Assessment of Treatment-Resistant Depression
Clinical panel experts recommended using the following set of clinical tools and tests to identify and diagnose TRD.
- Depression severity scales such as Montgomery-Asberg Depression Rating Scale (MADRS) and psychiatrist-rated scales. Montgomery-Asberg Depression Rating Scale has long been used by physicians for assessing depression, the advantage of MADRS is that avoids the drawbacks of the HAM-D score and is more robust. It is used mainly to detect any patients' response changes to antidepressant therapy with high sensitivity and is positively correlated to change in degree of depression (18).
- Hypomania check list: The hypomania checklist has long been used in many countries and in different languages to differentiate bipolar depression from MDD. This is important as manic/psychotic symptoms in depression should not be confused with TRD (19).
- Suicide scale [e.g., Beck's Scale for Suicide Ideation or Columbia Suicide Severity Rating Scale (C-SSRS)]. Suicide ideation scales are mainly used to monitor patient's health and to predict the risk of actual suicide for timely intervention (20). The BSS is one of the most reliable tools to predict a patient's risk and plan for suicide. The C-SSRS is also a sensitive scale to use especially that it is sensitive to change of suicidal ideation over treatment time and with the use of medication (21).
- Complete blood count (CBC), liver and kidney function tests, lipid and glycemic profiles: Complete blood count (CBC), liver and kidney function test and lipid and glycemic profiles; all these tests can be used and are done to eliminate any disease that could precipitate symptoms of depression (22).
- Thyroid function test: Regarding thyroid profiling; it is established through a wide volume of research that hypothyroidism presents with some depressive symptoms, in a study conducted by Bathla et al. 56% of males and 64% of females with hypothyroidism presented with some symptoms of depression and anxiety (23).
- Electrocardiogram: An electrocardiogram could be beneficial since stress (a component of MDD) is linked to heart disease. Not only that; depression onset is often seen in up to 40% of patients after a major cardiac event. Therefore, an ECG could be of use to determine heart health of patients and to stratify patients who could be at risk of developing MDD or TRD (24).
- Brain imaging techniques like magnetic resonance imaging (MRI): Recently, brain imaging using MRIs or CT scans have been utilized in the diagnosis of MDD especially in the elderly. This is because some cases of depression indicate an underlying mental disease as Parkinson's, Alzheimer's and Pick's disease; moreover, geriatric depression has been associated with leukoencephalopathy that can be detected using brain imaging techniques (25).
The panel highlighted the importance of periodic performance of most of the above tests upon prescribing ADs. In addition to the aforementioned tests, the panel also recommends performing the following tests based on clinician's discretion and the patient profile, as follows:
- Assessing vitamin D plasma levels
- Assessing sex hormones plasma levels
- Toxicological analysis of blood and urine samples
Principles of Management
Upon careful assessment of the condition, the expert panel agreed that psychiatric hospitalization is warranted in severe cases that fall under the umbrella of one of the following:
- Catatonic cases
- Patients with high suicidal tendency
- Severe psychotic symptoms
- Advanced cases of MDD
- The presence of severe uncontrolled comorbid medical conditions
- Insufficient familial support to the patient
Therapeutic Options for Treatment-Resistant Depression and Comorbid Conditions
Pharmacotherapeutic Options of Comorbid Conditions
For patients suffering from comorbid conditions, the expert panel recommends the following:
Patients suffering from anxiety and its features are recommended to receive benzodiazepines. Buspirone and pregabalin are also available options. Anxiety and depression often go hand in hand; therefore, a multi-modal treatment approach for handling both illnesses are often recommended. The evidence in the treatment of anxiety disorders greatly points to SSRIs, SNRIs and benzodiazepines. Benzodiazepines have long been used as anxiolytics as they demonstrate a relatively high safety and tolerability profile, they also have a rapid onset of action and manage acute anxiety symptoms and somatic complaints according to the NICE guidelines. The common issue physicians and patients face with benzodiazepines is dependence and abuse; thus, benzodiazepines should be preferentially used for a short amount of time (26).
The NICE guidelines usually recommend pregabalin in patients with anxiety if they do not tolerate SSRIs and SNRIs; pregabalin is an anti-convulsant and is also used for neuropathic pain; the advantage of pregabalin over benzodiazepines is that it does not cause dependance; however, sudden discontinuation may cause confusion. Buspirone, a non-benzodiazepine alternative is also prescribed for anxiety symptoms; the evidence regarding its efficacy in comparison to benzodiazepines is conflicting; however, it does not cause sedation, withdrawal symptoms or addiction as benzodiazepines (27).
Patients with depression or TRD frequently suffer from sleep disturbances; therefore, a sleep-aid can be used to overcome this symptom. Benzodiazepines; although excellent sleep-aids; often cause residual daytime sleepiness or “hangover”, high doses of benzodiazepines also cause cognitive impairment and respiratory depression therefore, pose a risk; in contrast to hypnotic agent zolpidem that lacks effect of residual day-time sedation or psycho-motor impairment. Zopiclone, another hypnotic agent; is also free of any day-time sleepiness side effect but slightly impairs psychomotor function especially at high doses. Both agents are reported to be tolerated, efficacious, safe and have low rates of dependence or abuse (28).
Other non-benzodiazepines that also act as sedatives are trazodone (an antidepressant from a class of serotonin modulators) and low dose quetiapine (an atypical anti-psychotic). Quetiapine has a wide array of indications; it has the advantage of ameliorating anxiety symptoms so can be used in TRD comorbid with anxiety, chronic pain and PTSD. In depression; 27 patients in a MDD episode were administered low dose quetiapine along with venlafaxine or escitalopram, by the end of the 4 weeks test time; sleep parameters had definitely improved in all patients (29). A head-to-head comparative study between trazodone and low dose quetiapine in hospitalized psychiatric patients at St. Helena's Hospital suffering from insomnia revealed that trazodone is a superior agent in patients with depressive symptoms and offers higher improvement in sleep parameters than quetiapine (30).
Patients at high risk of self-inflicted injury are recommended to receive lithium, benzodiazepine, or second-generation antipsychotic medication. This is because second benzodiazepines generation anti-psychotics as clonazepam have a mood stabilizing effect and reduce impulsivity and mood swings (31).
The clinical committee members recommended that patients should be maintained on their ongoing antidepressant medication for a period of 9–12 months following the achievement of clinical remission.
Patients suffering from the following conditions are recommended to receive a longer course of treatment:
- Long period to reach remission
- History of 2 prior depression episodes
- History of early relapse after treatment discontinuation
- Presence of suicidal tendency, symptoms of psychosis, family history of suicide or mood disorders or comorbid psychiatric condition.
- Resistance to an antidepressant medication when given at proper dose and adequate duration.
Therapeutic Options of Patients Suffering From TRD
The panel experts highlighted the available treatment options for patients suffering from TRD. The available therapeutic options are captured in Figure 1.
Pharmacological Strategies in Treatment-Resistant Depression
Switching involves shifting to another antidepressant medication, either within the same class or from a different class. Switching to a medication within the same class is undertaken to obtain a different pharmacological property, while switching to another class usually yields a different neurochemical effect. This strategy is tailored to suit individual patient needs and preferences (5).
According to evidence gathered about switching treatment in TRD; switching has certain pros over augmentation therapy; first it carries lower risk of drug-drug interactions, has higher patient adherence, moreover, it is preferred for patients who suffered severe side effects from first line medication and displayed partial or no response.
Only two major trials have been conducted to observe switching of medications in TRD, the first was about patients who had previously failed two antidepressants (mostly SSRIs) and were switched to either SSRI paroxetine or SNRI venlafaxine; response rates were 33 and 52%, respectively while remission rates were 20 and 42%. Other studies involved switching from SSRI to extended-release venlafaxine and switching from an SSRI to mirtazapine or sertraline, both studies showed no significant difference in depressive symptoms.
The panel experts recommend switching to be carried out in the following situations:
- Lack of response or poor tolerance to initial treatment
- Prior response to the introduced medication
The clinical experts highlighted 3 different types of switching strategies, with concurrent switching being the most recommended, except for medications belonging to monoamine oxidase inhibitor (MAOIs) class. These strategies are captured in Figure 2 (32).
Figure 2. Schematic diagrams of switching strategies. (A) Concurrent switch is best suited for patients demonstrating partial response, where simultaneous change in the dose of both medications is implemented. (B) Overlapping switch is suitable for patients who demonstrate partial response, where the dose of the original medication is maintained until the second medication reaches its optimal dose. (C) Sequential switch is considered to be the safest switching technique, as it is the least likely to cause any interaction. In this strategy, one medication is substituted with another. This technique is used in patients who do not respond to initial treatment.
Recommendations for switching antidepressant medications are captured in Figure 3.
Figure 3. Recommendations for switching antidepressant medications. If patient is responsive continue on current treatment, if not consider combination strategies** Adapted from the French guidelines. **Combination strategy = The panel recommends the use of combination strategy in patients with partial response after adequate treatment with a medication for a period of 2–4 weeks.
Combination strategies usually involve using 2 different antidepressant medications belonging to different classes and having different pharmacodynamic profiles (33).
The panel recommends the use of combination strategy in patients with partial response after adequate treatment with a medication for a period of 2–4 weeks (4–6 weeks if with TCAs).
The recommended first-line combination strategy involves mirtazapine plus one of the following:
- Selective serotonin reuptake inhibitor.
- Serotonin–norepinephrine reuptake inhibitor.
- Tricyclic antidepressant.
Augmentation strategies refers to the addition of non-standard antidepressant medications, like lithium and quetiapine, to enhance the outcome of classical antidepressants (34). The panel summarized the medications and lines of choice in Table 1.
The panel recommends this strategy in patients who demonstrate partial response after 2–4 weeks of treatment (4–6 weeks with TCA as they have a delayed effect than newer agents).
The panel recommends adding lithium or quetiapine to improve efficacy of the antidepressant medication.
The panel recommends a second choice of thyroid hormone supplementation in addition to serotonin–norepinephrine reuptake inhibitors or tricyclic antidepressants, and with selective serotonin reuptake inhibitors or mirtazapine at a later stage.
The recommended dose of thyroid hormone supplementation is between 25 and 60 ug/day of liothyronine (L-T3) and is required to achieve TSH levels ranging between 0.1 and 1 ug/L. Prior to initiating treatment, the panel recommends performing the following assessments:
- Physical examination
- Electrocardiogram (ECG)
- Thyroid-stimulating hormone (TSH) levels.
Treatment Sequence for Depression Dimensions
Major depressive disorder is a multidimensional disorder that originates from multiple etiologies. The symptom dimension may act as predictor of antidepressant treatment response (35).
The panel recommendations for the first and second lines of treatment of several depression dimensions are illustrated in Table 2.
Brain Stimulation Techniques
The panel selected ECT/BST, and repetitive transcranial magnetic stimulation (rTMS) as the preferred brain stimulation techniques that are either used alone or in combination with antidepressants. The panel agreed that ECT/BST represent effective approaches to prevent relapse, either alone or in combination. Recommendations of brain stimulation techniques are as follows:
BST is recommended for resistant cases after failure of 3 adequately used antidepressants.
Novel Therapeutic Agents
Esketamine, the S enantiomer of ketamine, is a N-methyl-D-aspartate (NMDA) receptor antagonist that has higher affinity to the receptor compared to the R enantiomer and the racemic mixture of ketamine (36). In the form of a nasal spray, this molecule has recently gained approval in the United States for the indication of TRD as well as by the EMA in Europe for the indication of TRD, bringing hope to patients who suffer from the condition (37).
Esketamine, in combination with SSRIs or SNRIs, is indicated for the treatment of TRD in patients who did not respond to least 2 different classes of antidepressant medications (38).
Strategies to Prevent Relapse
A relapse is the return of depressive symptoms to patients. Relapse could be early or delayed. In the former, symptoms return is expected to be within the first 3–12 months, while the latter refers to the emergence of new depressive episodes following remission or initial short-term improvement in symptoms (39).
It is of importance to have measures to prevent relapse from the first relapse episode. With regard to preventive strategies, the following has been highlighted:
The panel recommends the use of ECT and lithium as effective first-line options to prevent relapse.
The panel recommends the use of lamotrigine or quetiapine as second-line options to prevent relapse.
The panel recommends the following strategies when patients achieve full remission:
- Continuous assessment of patients' adherence to treatment.
- Continuous assessment of social functioning of patients.
- Continuous assessment of quality of life (QoL) of patients.
The panel recommends the following complementary approaches for relapse and recurrence prevention:
- Undertaking regular physical exercises and activities.
- Eating healthy food
- Control physical illness (e.g., hypertension, diabetes, etc.…)
Treatment resistant depression is regarded as patients failing 2 subsequent antidepressant treatments (38); in Egypt TRD's definition is slightly altered to the latter by the addition of failure of 6–12 sessions of ECT or BST (Brain Stimulation Techniques). Approximately 60–70% of depressed patients do not respond to first line treatment and more than a third become treatment resistant. However, TRD should not be confused with “pseudo-resistance”. This means that patient-related factors that might contribute treatment failure should be taken into account before deeming their depression as “resistant”. These factors are numerous, however inadequate dosing, compliance, follow-up and primary mis-diagnosis are prime examples (38). Another review also added other patient traits; the presence of comorbid psychiatric illnesses as OCD (Obsessive Compulsive Disorder), bipolarity, anxiety and eating disorders as well as the presence of psycho-somatic disorders as Fibromyalgia and IBS (Irritable Bowel Syndrome), all of which must be assessed carefully (with several available diagnostic tools) as they may lead to high rates of depression recurrence and severity; higher severity of depressive illness and the higher rates of relapses in between remission periods is definitely a precipitating factor for TRD (39).
The panel urges that patients are monitored for both psychiatric and somatic diseases; this is reinforced by Kornstein's data who reported that patients with hypothyroidism and depression had higher remission rates when properly treated for under-active thyroid, this agrees with the panel's recommendation in augmenting therapy with T3 hormone supplementation. Patient history and concurrent medications must be known as some drugs such as gluco-corticosteroids and anti-inflammatories are associated with causing depressive symptoms (39). Ergo, the panel suggests using a list of tools and tests as MRIs, blood work, organ function tests etc. to monitor for certain patient conditions that may cause depression treatment failure or increase severity of the illness.
The panel agrees with the international guidelines for hospitalization indications in patients with TRD, this is because hospitalization prevents further complications that may be caused if TRD and/or its comorbidities are not under continuous medical supervision (8). A study conducted in Finland on a population of hospitalized patients as a result of depression followed-up patients up to 24 years after discharge to evaluate their outcomes. Of about 15,000 patients followed-up; only 2,567 died by suicide with an overall cumulative risk of suicide of 6.13%; which is considerably lower than depressed patients who remain unhospitalized (40).
Regarding comorbid mental illnesses with depression the panel recommends using several drugs in addition to antidepressants; the anxiolytics used is in line with the Canadian clinical practice guidelines; generally, benzodiazepines are fit for all anxiety disorders; Buspirone is indicated for a wide range of anxiety diseases as panic disorder, social anxiety, OCD (Obsessive Compulsive Disorder), GAD (Generalized Anxiety Disorder) and PTSD (Post-traumatic Stress Disorder), Pregabalin however, is used as second line treatment if first line drugs are not tolerated. For sleep disorders and self-harm comorbid with TRD, the panel's recommendations are based on clinical experience; which of course at times conflicts with published research. A Cochrane meta-analysis had similar documented patients who were prescribed drugs similar to the panel's recommendations as atypical anti-psychotics and benzodiazepines for both self-harm and sleep disorders (41).
Physicians however, must be aware of which drug to add to the patient's treatment plan and patient monitoring and continuous follow-up is crucial to their wellbeing. In Table 3, the panel has several recommendations of which medications to prescribe if TRD were associated with any other clinical issue such as sleep disturbances, suicide ideation, anxious features etc. Mirtazapine is an excellent antidepressant with a wide array of indications (and off-label uses) and has demonstrated superiority to tricyclic antidepressants due to its lack of any anti-cholinergic, adrenergic and serotonin-mediated side effects; clinical evidence has proved that it has transferred the treatment of depression. In comparison to tricyclic antidepressants as amitriptyline, clomipramine, doxepin and serotonin modulator trazodone, the clinical effect of mirtazapine was similar and at times superior, not only that, but it is also strongly advocated in cases of depression with poor sleep scores in which mirtazapine improved drastically in comparison to placebo. According to these findings, mirtazapine's adverse effects as dry mouth, increased appetite and weight gain should be weighed together with its high safety and effective treatment profile, when exploring other drugs to prescribe/augment/combine with the current treatment profile (42).
Another interesting agent that can be used and is recommended by Egyptian psychiatrists is agomelatine, one of the first melatonergic agents and a 5-hydroxytryptamine receptor (5-HT2C) antagonist both of which act harmoniously to adjust disrupted circadian rhythms (sleep cycles) typically found in depressive illness. As mentioned above, depressed patients must be closely monitored to avoid any consequences unintentionally caused by treatment; agomelatine should not be used in patients with a compromised liver and in healthy patients, liver function tests must be routinely done at the beginning of treatment and subsequently at 6 weeks, 12 weeks and 6 months as recommended by the EMA (European Medicines Agency) (43).
Moving forward, a pharmacological treatment algorithm was devised as mentioned above in Figure 3; there are several strategies that physicians can adhere to when approaching TRD, these include switching, combination or augmentation strategies. A study in 2001 evaluated patients wth low response to Fluoxetine 20 mg/day who were switched to mianserin 60 mg/day. The results were intermediate but were still sound with depression scores lower by 1.8 in the mianserin group than those who continued on Fluoxetine. The same study also had a third treatment arm with patients on fluoxetine therapy combined with mianserin (=combination strategy) in which the depression score plummeted by 4.6 in the combined treatment group; this is a commonly observed phenomenon in combination strategies as both drugs synergistically act to create a larger overall effect in managing symptoms especially of a multi-modal disease as depression (44).
Furthermore, augmentation strategy is adding a different class of medication to a current antidepressant; this was done in a study where randomized depressed patients who remitted from ECT.They received placebo, lithium or lithium with nortriptyline; 84% relapsed on placebo, 60% on lithium monotherapy and 39.1% on the combination therapy which consolidates the fact that combination therapy with non-antidepressant agent proves useful in treatment of depression as well as preventing relapses (45). There is also evidence that suggests that Lithium decreases the risk of suicide in depressed patients (46).
There are other methods of treatment in TRD to resort to such as ECT (a brain stimulation technique) or the use of esketamine (a relatively novel therapeutic agent). ECT therapy has long been recommended by the British guidelines of 2000 for severe cases of depression especially those who have failed two or more drugs (TRD), rTMS is recommended second to ECT but must be done by a team of specialists. Ghasemi made a more interesting discovery when comparing patients who received three sessions of ECT vs. those who received low dose esketamine over 3 days; results supported that both treatments although comparable, esketamine had a more rapid and more pronounced resolution of symptoms (47). The use of esketamine is not yet approved in Egypt; although it has long been approved by the FDA in the United States and the EMA in Europe for its relative safety and efficacy; moreover, adverse effects of dissociation, vertigo and dizziness from esketamine usually resolved on the same day, shortly after administration; (48) future-wise; the use of esketamine (only as nasal spray) must be warranted in Egypt due to its pronounced effect with patients feeling better within hours of administration and lower relapse rates as maintenance treatment all of which is vital for a TRD patient.
Following achieving remission for depression; a major challenge is to prevent relapse of depressive episodes; the use of lithium is widely agreed upon in patients who were suicidal, ECT is proposed for patients with frequent relapses. Physiological wellbeing is also an aspect to be considered; any emerging or residual mental or physical illness should be tended to in order to prevent relapse (46).
Like all studies, this study carries its own strengths and limitations. Surely the first strength of this study is that this is the first consensus of guidelines between Egyptian psychiatrists for the treatment of TRD; the panel's recommendations came from practicing them on TRD patients in an expert clinical setting. The limitation of this study is that the panel constituted of only eight doctors who only represent a small group of psychiatrists from a much larger number in Egypt; additionally, there is no scientifically exact or official definition of TRD or for its treatment of TRD in Egypt or world-wide (internationally) to base these recommendations on; they were merely observations collected by the panel experts.
The integration of clinical practice with the latest updates of clinical studies yields the best outcomes for patients. TRD puts a significant burden on the patient, therefore, it is always best to manage the condition with careful review and step-wise approach. The development of recent pharmaceutical options for patients with TRD ushers a new area to tackle this condition.
Data Availability Statement
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.
All authors listed have made a substantial, direct, and intellectual contribution to the work, participated in its writing and approved it for publication.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyt.2022.797150/full#supplementary-material
1. Uher R, Payne J, Pavlova B, Perlis R. Major depressive disorder in DSM-5: implications for clinical practice and research of changes from DSM-IV. Depress Anxiety. (2013) 31:459–71. doi: 10.1002/da.22217
2. Bains N, Abdijadid S. Major Depressive Disorder. Treasure Island, FL: StatPearls Publishing (2021) Available online at: https://www.ncbi.nlm.nih.gov/books/NBK559078/ (accessed April 20, 2021).
3. Available, online at: https://www.who.int/en/news-room/fact-sheets/detail/depression (accessed December 24, 2021).
4. Odejimi O, Tadros G, Sabry N. A systematic review of the prevalence of mental and neurocognitive disorders amongst older adults' populace in Egypt. Middle East Curr Psychiatry. (2020) 27:47. doi: 10.1186/s43045-020-00055-8
5. Fava M. Switching treatments for complicated depression. J Clin Psychiatry. (2010) 71:e04. doi: 10.4088/JCP.8001tx14c
6. Voineskos D, Daskalakis ZJ, Blumberger DM. Management of treatment-resistant depression: challenges and strategies. Neuropsychiatr Dis Treat. (2020) 16:221–34. doi: 10.2147/NDT.S198774
7. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. (2006) 163:1905–17. doi: 10.1176/ajp.2006.163.11.1905
8. Bennabi D, Charpeaud T, Yrondi A, Genty JB, Destouches S, Lancrenon S, et al. Clinical guidelines for the management of treatment-resistant depression: French recommendations from experts, the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental. BMC Psychiatry. (2019) 19:262. doi: 10.1186/s12888-019-2237-x
9. Hassan A, Farmer K, Brahm N, Neas B. Evaluating antidepressant treatment prior to adding second-line therapies among patients with treatment-resistant depression. Int J Clin Pharm. (2016) 38:429–37. doi: 10.1007/s11096-016-0272-y
10. de Villiers MR, de Villiers PJ, Kent AP. The Delphi technique in health sciences education research. Med Teach. (2005) 27:639–43. doi: 10.1080/13611260500069947
11. Gaynes B, Lux L, Gartlehner G, Asher G, Forman-Hoffman V, Green J, et al. Defining treatment-resistant depression. Depress Anxiety. (2019) 37:134–45. doi: 10.1002/da.22968
12. Available, online at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017090s078lbl.pdf (accessed December 24, 2021).
13. Available, online at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018936s091lbl.pdf (accessed December 24, 2021).
14. Available, online at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020699s107lbl.pdf (accessed December 24, 2021).
15. MacGillivray S. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ. (2003) 326:1014. doi: 10.1136/bmj.326.7397.1014
16. Zajecka J, Albano D. SNRIs in the management of acute major depressive disorder. J Clin Psychiatry. (2004) 65:11–8.
17. Gronemann F, Petersen J, Alulis S, Jensen K, Riise J, Ankarfeldt M, et al. Treatment patterns in patients with treatment-resistant depression in Danish patients with major depressive disorder. J Affect Disord. (2021) 287:204–13. doi: 10.1016/j.jad.2021.03.029
18. Iannuzzo R, Jaeger J, Goldberg J, Kafantaris V, Sublette M. Development and reliability of the HAM-D/MADRS interview: an integrated depression symptom rating scale. Psychiatry Res. (2006) 145:21–37. doi: 10.1016/j.psychres.2005.10.009
19. Forty L, Smith D, Jones L, Jones I, Caesar S, Fraser C, et al. Identifying hypomanic features in major depressive disorder using the hypomania checklist (HCL-32). J Affect Disord. (2009) 114:68–73. doi: 10.1016/j.jad.2008.07.017
20. Chioqueta A, Stiles T. Psychometric Properties of the Beck Scale for Suicide Ideation: A Norwegian Study With University Students Trondheim: Taylor & Francis Company (2021).
21. Posner K, Brown G, Stanley B, Brent D, Yershova K, Oquendo M, et al. The Columbia–suicide severity rating scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. (2011) 168:1266–77. doi: 10.1176/appi.ajp.2011.10111704
22. Nobis A, Zalewski D, Waszkiewicz N. Peripheral markers of depression. J Clin Med. (2020) 9:3793. doi: 10.3390/jcm9123793
23. Bathla M, Singh M, Relan P. Prevalence of anxiety and depressive symptoms among patients with hypothyroidism. Indian J Endocrinol Metab. (2016) 20:468. doi: 10.4103/2230-8210.183476
24. Dhar A, Barton D. Depression and the link with cardiovascular disease. Front Psychiatry. (2016) 7:33. doi: 10.3389/fpsyt.2016.00033
25. Zubenko G, Sullivan P, Nelson J, Belle S, Huff F, Wolf G. Brain imaging abnormalities in mental disorders of late life. Arch Neurol. (1990) 47:1107–11.
26. Dunlop B, Davis P. Combination treatment with benzodiazepines and SSRIs for comorbid anxiety and depression: a review. Prim Care Companion J Clin Psychiatry. (2008) 10:222–8. doi: 10.4088/PCC.v10n0307
27. Hoge E, Ivkovic A, Fricchione G. Generalized anxiety disorder: diagnosis and treatment. BMJ. (2012) 345:e7500. doi: 10.1136/bmj.e7500
28. Wagner J, Wagner M. Non-benzodiazepines for the treatment of insomnia. Sleep Med Rev. (2000) 4:551–81. doi: 10.1053/smrv.2000.0126
29. Wine J, Sanda C, Caballero J. Effects of quetiapine on sleep in nonpsychiatric and psychiatric conditions. Ann Pharmacother. (2009) 43:707–13. doi: 10.1345/aph.1L320
30. Doroudgar S, Chou T, Yu J, Trinh K, Pa J, Perry P. Evaluation of trazodone and quetiapine for insomnia. Primary Care Compan CNS Disord. (2013) 15:PCC.13m01558. doi: 10.4088/PCC.13m01558
31. Papakostas G. Managing partial response or nonresponse. J Clin Psychiatry. (2009) 70 (Suppl. 6):16–25. doi: 10.4088/JCP.8133su1c.03
32. Malhi GS, Hitching R, Berk M, Boyce P, Porter R, Fritz K. Pharmacological management of unipolar depression. Acta Psychiatr Scand Suppl. (2013) 17:6–23. doi: 10.1111/ac–s.12122
33. López-Muñoz F, Álamo C, García-García P. Combination strategies in treatment-resistant depression. In: López-Muñoz F, Srinivasan V, de Berardis D, Álamo C, Kato T, editors. Melatonin, Neuroprotective Agents and Antidepressant Therapy. New Delhi: Springer (2016).
34. Carvalho AF, Cavalcante JL, Castelo MS, Lima MC. Augmentation strategies for treatment-resistant depression: a literature review. J Clin Pharm Ther. (2007) 32:415–28. doi: 10.1111/j.1365-2710.2007.00846.x
35. Vares EA, Salum GA, Spanemberg L, Caldieraro MA, Fleck MP. Depression dimensions: integrating clinical signs and symptoms from the perspectives of clinicians and patients. PLoS ONE. (2015) 10:e0136037. doi: 10.1371/journal.pone.0136037
36. Swainson J, Thomas RK, Archer S, Chrenek C, MacKay MA., Baker G, et al. Esketamine for treatment resistant depression. Expert Rev Neurother. (2019) 19:899–911. doi: 10.1080/14737175.2019.1640604
37. Fedgchin M, Trivedi M, Daly EJ, Melkote R, Lane R, Lim P, et al. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol. (2019) 22:616–30. doi: 10.1093/ijnp/pyz039
38. Daniel S, Papakostas G, Trivedi M. Treatment-resistant depression. J Clin Psychiatry. (2006) 67 (Suppl 6):16–22.
39. Kornstein S, Schneider R. Clinical features of treatment-resistant depression. J Clin Psychiatry. (2001) 62:18–25.
40. Aaltonen K, Isometsä E, Sund R, Pirkola S. Decline in suicide mortality after psychiatric hospitalization for depression in Finland between 1991 and 2014. World Psychiatry. (2018) 17:110–2. doi: 10.1002/wps.20501
41. Storebø OJ, Stoffers-Winterling JM, Völlm BA, Kongerslev MT, Mattivi JT, Jørgensen MS, et al. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev. (2020) 5:1–512. doi: 10.1002/14651858.CD012955.pub2
42. Kasper S, Praschak-Rieder N, Tauscher J, Wolf R. A risk-benefit assessment of mirtazapine in the treatment of depression. Drug Safety. (1997) 17:251–64. doi: 10.2165/00002018-199717040-00005
43. de Bodinat C, Guardiola-Lemaitre B, Mocaër E, Renard P, Muñoz C, Millan M. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov. (2010) 9:628–42. doi: 10.1038/nrd3140
44. Ferreri M, Lavergne F, Berlin I, Payan C, Puech A. Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta Psychiatr Scand. (2008) 103:66–72. doi: 10.1034/j.1600-0447.2001.00148.x
45. Sackeim H, Haskett R, Mulsant B, Thase M, Mann J, Pettinati H, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy. JAMA. (2001) 285:1299. doi: 10.1001/jama.285.10.1299
46. Anderson I, Ferrier I, Baldwin R, Cowen P, Howard L, Lewis G, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol. (2008) 22:343–96. doi: 10.1177/0269881115581093
47. Ghasemi M, Kazemi M, Yoosefi A, Ghasemi A, Paragomi P, Amini H, et al. Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder. Psychiatry Res. (2014) 215:355–61. doi: 10.1016/j.psychres.2013.12.008
48. Katz E, Hough D, Doherty T, Lane R, Singh J, Levitan B. Benefit–risk assessment of esketamine nasal spray vs. placebo in treatment-resistant depression. Clin Pharmacol Ther. (2020) 109:536–46. doi: 10.1002/cpt.2024
Keywords: depression, treatment resistance, guidelines, clinical psychiatry, neuropharmacology
Citation: Abdel-Wahab M, Okasha T, Shaheen M, Nasr M, Molokheya T, Omar AE, Rabie MA, Samy V, Hamed H and Ali M (2022) Clinical Guidelines of the Egyptian Psychiatric Association for the Management of Treatment-Resistant Unipolar Depression in Egypt. Front. Psychiatry 13:797150. doi: 10.3389/fpsyt.2022.797150
Received: 26 October 2021; Accepted: 04 February 2022;
Published: 14 March 2022.
Edited by:Christos Theleritis, National and Kapodistrian University of Athens, Greece
Reviewed by:Domenico De Berardis, Mental Health Center (CSM) and Psychiatric Service of Diagnosis and Treatment (SPDC), Italy
Lucie Bartova, Medical University of Vienna, Austria
Copyright © 2022 Abdel-Wahab, Okasha, Shaheen, Nasr, Molokheya, Omar, Rabie, Samy, Hamed and Ali. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Tarek Okasha, firstname.lastname@example.org